168 related articles for article (PubMed ID: 19645647)
1. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
[TBL] [Abstract][Full Text] [Related]
2. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
[TBL] [Abstract][Full Text] [Related]
5. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
Häkkinen M; Heikman P; Ojanperä I
Forensic Sci Int; 2013 Oct; 232(1-3):11-5. PubMed ID: 24053859
[TBL] [Abstract][Full Text] [Related]
6. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
Larance B; Dietze P; Ali R; Lintzeris N; White N; Jenkinson R; Degenhardt L
Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
[TBL] [Abstract][Full Text] [Related]
7. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.
Larance B; Mattick R; Ali R; Lintzeris N; Jenkinson R; White N; Kihas I; Cassidy R; Degenhardt L
Drug Alcohol Rev; 2016 Jan; 35(1):83-91. PubMed ID: 26450513
[TBL] [Abstract][Full Text] [Related]
8. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
10. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
Bazazi AR; Yokell M; Fu JJ; Rich JD; Zaller ND
J Addict Med; 2011 Sep; 5(3):175-80. PubMed ID: 21844833
[TBL] [Abstract][Full Text] [Related]
11. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
14. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
Bruce RD; Govindasamy S; Sylla L; Kamarulzaman A; Altice FL
Am J Drug Alcohol Abuse; 2009; 35(2):68-72. PubMed ID: 19212931
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
Orman JS; Keating GM
Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
19. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
